


Prostaglandin E2

Cat. No.:	HY-101952	
CAS No.:	363-24-6	
Molecular Formula:	C ₂₀ H ₃₂ O ₅	
Molecular Weight:	352.47	
Target:	Prostaglandin Receptor; Endogenous Metabolite	
Pathway:	GPCR/G Protein; Metabolic Enzyme/Protease	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (283.71 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass		1 mg	5 mg	10 mg
	Concentration				
	1 mM		2.8371 mL	14.1856 mL	28.3712 mL
	5 mM		0.5674 mL	2.8371 mL	5.6742 mL
	10 mM		0.2837 mL	1.4186 mL	2.8371 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Prostaglandin E2 is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.

IC₅₀ & Target

EP₂ Receptor Human Endogenous Metabolite

In Vitro

PGE2 shows inhibition of IL 2 production in the mixture of irradiated and nonirradiated T lymphocytes. PGE2 (0.1-10 μM)

dose-dependently inhibits the production of IL 2. PGE2 acts during the inductive phase of activation of suppressor cells. Preincubation of T lymphocytes with PGE2 induces cells that suppress IL 2 production and PHA proliferation^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PGE2 (0.3 µg/k, i.p.) significantly reduces the number of peritoneal macrophages undergoing phagocytosis of the methacrylate microbeads in rats^[2]. PGE2 (0.1 mg/min, i.a.) increases renal blood flow. PGE2 produces a biphasic change in renal vascular resistance, vasodilatation starts at 0.01 mg/min and is maximal at about 3 mg/min, while at the highest dose used (20 mg/min) PGE2 induces renal vasoconstriction^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

Lymphocytes in CM (1×10^6 cells/mL) are distributed in microculture plates (100 µL) in triplicate in the presence of PGE-treated T cells or medium-treated T cells and stimulated with PHA-P at various mitogenic doses. After 72 hr, cultures are pulsed with 1 µCi [³H]thymidine per well (specific activity 5 Ci/mM) for 16 to 18 hr, collected with amicroprecipitator, dried, and counted in a liquid scintillation counter.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[2]

Male Sprague Dawley rats (200-250 g) are used throughout the study. For 3 consecutive days rats in the experimental groups receive a daily intraperitoneal injection of either PGE2 (0.3 µg/kg body weight (BW)), the prostaglandin inhibitor meclofenamate (10 mg/kg BW) or the prostaglandin precursor arachidonic acid (0.3 µg/kg BW). To determine whether or not 0.3 µg/kg BW of a fatty acid produces nonspecific effects, the biologically inactive fatty acid 11, 14, 17-eicosatrienoic acid is also administered to a group of rats. Rats in the control group receive an equivalent volume (2.0 mL/kg BW) of the vehicle. On the third day, 3 mL of a suspension containing 1.2×10^6 fluorescent methacrylate microbeads/mL of PBS are injected intraperitoneally (ip) into each rat. Six hours later all animals are given ip a regular dose of their respective treatment. Peritoneal exudate cells are harvested 19-22 hr later.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Exp Clin Cancer Res. 2020 Jun 16;39(1):113.
- Front Microbiol. 20 May 2020.
- J Cell Commun Signal. 2020 Jun;14(2):175-192.
- J Cell Commun Signal. 2020 Jan 10.
- Oncotargets Ther. 2020 Aug 18;13:8197-8208.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Chouaib S, et al. The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol. 1984 Apr;132(4):1851-7.
- [2]. Fernandez-Repollet E, et al. In vivo effects of prostaglandin E2 and arachidonic acid on phagocytosis of fluorescent methacrylate microbeads by rat peritoneal macrophages. J Histochem Cytochem. 1982 May;30(5):466-70.
- [3]. Haylor J, et al. Renal vasodilator activity of prostaglandin E2 in the rat anaesthetized with pentobarbitone. Br J Pharmacol. 1982 May;76(1):131-7.

Caution: Product has not been fully validated for medical applications. For research use only.

India Contact:

Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444

Email: customerservice@lifetechindia.com Website: www.lifetechindia.com